Evidence map›Paper›PMID 35068861›Full record

ArticleWorld journal of gastroenterology2021

Disease control and failure patterns of unresectable hepatocellular carcinoma following transarterial radioembolization with yttrium-90 microspheres and with/without sorafenib.

Ajalaya Teyateeti, Armeen Mahvash, James Long, Mohamed Abdelsalam, Rony Avritscher, Ahmed Kaseb, Bruno Odisio, Gregory Ravizzini, Devaki Surasi, Achiraya Teyateeti and 2 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of gastroenterology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 51% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 2 countries.

Ajalaya TeyateetiDepartment of Nuclear Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States.
Armeen MahvashDepartment of Interventional Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States.
James LongDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States.
Mohamed AbdelsalamDepartment of Interventional Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States.
Rony AvritscherDepartment of Interventional Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States.
Ahmed KasebDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States.
Bruno OdisioDepartment of Interventional Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States.
Gregory RavizziniDepartment of Nuclear Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States.
Devaki SurasiDepartment of Nuclear Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States.
Achiraya TeyateetiDivision of Radiation Oncology, Department of Radiology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand.
Homer MacapinlacDepartment of Nuclear Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States.
Srinivas Cheenu KappadathDepartment of Imaging Physics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States. skappadath@mdanderson.org.
The University of Texas MD Anderson Cancer Center · USMahidol University · THSiriraj Hospital · TH

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
NCI NIH HHS P30 CA016672
6 · The paper itself

Abstract

backgroundImpressive survival outcome of our previous study in unresectable hepatocellular carcinoma (HCC) patients undergoing yttrium-90 glass microspheres transarterial radioembolization (TARE) with/without sorafenib according to individuals' disease burden,

aimTo assess the tumor response, disease control and patterns of disease progression following TARE with/without sorafenib in unresectable HCC patients.

methodsThis retrospective study was conducted in successful TARE procedures with available pre- and post-treatment imaging studies (

resultsThe median radiologic follow-up time was 4.4 mo (range 0.5-48.8). In treated area, ORR was highest in

conclusionTARE with/without sorafenib according to individuals' disease burden provided DCR approximately 70% with intrahepatic progression as dominant failure pattern. Extrahepatic progression was more common in procedures with initially high disease burden.

Indexed as

Carcinoma, HepatocellularEmbolization, TherapeuticLiver NeoplasmsHumansMicrospheresRetrospective StudiesSorafenibTreatment OutcomeYttrium RadioisotopesSorafenibYttrium-90Yttrium RadioisotopesPattern of progressionRadioembolizationSelective internal radiotherapySorafenibTime to progressionTumor response

Identifiers

PMID35068861
PMCPMC8704272
OpenAlexW4200511244

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.